Disclosed are anti-HAAH antibodies and derivatives thereof conjugated to cytotoxic, cytostatic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods for the treatment of HAAH-expressing cancers, comprising administering to a subject the disclosed pharmaceutical compositions.
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
The present disclosure relates to methods of using biomarkers as early disease and patient outcome predictors. More particularly, the present disclosure encompasses methods of predicting cancer metastasis by detecting and/or quantifying aspartyl (asparaginyl) beta hydroxylase (HAAH) and matrix metalloproteinase 9 (MMP9) in a biological sample.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
3.
HAAH AND MMP-9 ARE COMPLEMENTARY CANCER BIOMARKERS AND PREDICTORS OF METASTASIS WHEN COMBINED
The present disclosure relates to methods of using biomarkers as early disease and patient outcome predictors. More particularly, the present disclosure encompasses methods of predicting cancer metastasis by detecting and/or quantifying aspartyl (asparaginyl) beta hydroxylase (HAAH) and matrix metalloproteinase 9 (MMP9) in a biological sample.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
4.
RADIO-IMAGING AND RADIO-THERAPY OF CANCER USING ANTIBODIES TO HAAH
The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.
The present invention encompasses methods of detecting exosomes comprising Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplates is further directed to methods diagnosing cancer by identifying exosomes comprising HAAH.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/553 - Support métallique ou recouvert d'un métal
The present invention is based on the discoveries that PAN-811 (1) reduces infarct volume, suppresses brain edema and decreases mortality associated with ischemia; (2) blocks veratridine-induced swelling and neuronal cell death; (3) chelates free calcium and inhibits MMP-9 activity; and (4) blocks calcium-induced neuronal cell death and suppresses glutamate- induced calcium influx into neuronal cells. More particularly, the present invention relates to methods for treating, ameliorating or preventing vasogenic and/or cytotoxic brain edema, by administering to a subject in need thereof certain thiosemicarbazone compounds or pharmaceutically acceptable salts thereof. An example of such a thiosemicarbazone is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811).
A01N 47/34 - Urées ou thiourées contenant les groupes N—CO—N ou N—CS—N contenant les groupes p. ex. biuretLeurs thio-analoguesProduits de condensation urée-aldéhyde
A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
The present invention relates to antiretroviral drug susceptibility tests that can be used to identify HIV-I -infected patients whose HIV-I virus will respond to treatment with maturation inhibitors. The invention further relates to novel vectors, host cells and compositions for carrying out these novel antiviral drug susceptibility tests. This invention also relates to the screening of candidate drugs for their capacity to inhibit cleavage of the HIV-I Gag polyprotein at the CA- SPl cleavage site.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/49 - Lentiviridae, virus de l'immunodéficience comme le VIH, virus visna-maedi, virus de l'anémie infectieuse équine
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
Thiazole derivatives represented by Formula (I) are disclosed, where R1, R2, R3, A, X, Y, Z, R6 and R7 are disclosed herein. These thiazole derivatives and pharmaceutical compositions comprising these derivatives are useful in the treatment of HIV mediated diseases and conditions.
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
Disclosed are certain peptide linkers for conjugating drugs to ligands, and the resulting drug-linker-ligand molecules and compositions thereof. The conjugated molecules useful for the targeted delivery of drugs to the desired cells, and allow for the intracellular release of the drug in cases where the targeted antigen is internalized via the trans Golgi network and not the lysosomal pathway.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.
Derivatives of pyrazolopyrimidine compounds represented by Formula (I) are disclosed. These pyrazolopyrimidine derivatives and pharmaceutical compositions comprising these derivatives are useful in the treatment of HIV mediated diseases and conditions.
Methods of preventing, treating or delaying the onset of HIV in a subject by administering to the subject novel pharmaceutically active arylmethyl pyrazolo[1,5-α ]pyrimidine amide derivatives, or pharmaceutical compositions containing the same are described. Additionally, compounds of novel pharmaceutically active arylmethyl piperazine pyrazolo[l,5-α]pyrimidine amide derivatives and their use for the manufacture of specific medicaments are described.
The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use of the compounds for the manufacture of medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are certain salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid, also known as 'DSB.' The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus ('HIV').
C07J 53/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par condensation avec des cycles carbocycliques ou par formation d'un cycle additionnel par une liaison directe entre deux atomes de carbone cycliques
14.
METHODS OF NEUROPROTECTION BY CYCLIN-DEPENDENT KINASE INHIBITION
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention concerns novel pharmaceutically active triterpene derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C2-8 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (HIV).
C07J 53/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par condensation avec des cycles carbocycliques ou par formation d'un cycle additionnel par une liaison directe entre deux atomes de carbone cycliques
16.
METHODS OF DIAGNOSING, PREDICTING THERAPEUTIC EFFICACY AND SCREENING FOR NEW THERAPEUTIC AGENTS FOR LEUKEMIA
The invention discloses methods for leukemia diagnosis and determining the effectiveness of certain therapies. The methods of the present invention also encompass a way to predict a subject's responsiveness to therapeutic interventions for leukemia, as well as to monitor relapse during treatment due to therapeutic resistance. Further, the methods disclosed can be used to screen for effective therapeutic agents or regimens, either generally or in a specific patient. Th invention also provides a unique diagnostic tool for leukemia.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
17.
PREPARATION OF PHARMACEUTICAL SALTS OF 3-O-(3',3'-DIMETHLSUCCINYL) BETULINIC ACID
This invention relates to a novel process for making 3-O-(3',3'- dimethylsuccinyl)betulinic acid ('DSB')- This invention also relates to methods of treating HIV and related diseases using pharmaceutical compositions comprising salt forms of DSB prepared according to the process of the present invention. The invention further relates to dosage forms of pharmaceutical compositions comprising salts of DSB made using the process of this invention.
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
C07J 53/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par condensation avec des cycles carbocycliques ou par formation d'un cycle additionnel par une liaison directe entre deux atomes de carbone cycliques
The present invention relates to methods of treating or preventing ischemia- related (i.e., neural cell hypoxia and/or hypoglycemic) conditions by administering to a patient in need thereof certain thiosemicarbazone compounds. More particularly, the present invention relates to methods of preventing or treating certain ischemia-related conditions, which may include Alzheimer's disease, Parkinson's disease, and ischemic states that are due to or result from such conditions as: coronary artery bypass graft surgery; global cerebral ischemia due to cardiac arrest; focal cerebral infarction; cerebral hemorrhage; hemorrhage infarction; hypertensive hemorrhage; hemorrhage due to rupture of intracranial vascular abnormalities; subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms; hypertensive encephalopathy; carotid stenosis or occlusion leading to cerebral ischemia; cardiogenic thromboembolism; spinal stroke and spinal cord injury; diseases of cerebral blood vessels, e.g., atherosclerosis, vasculitis; macular degeneration; myocardial infarction; cardiac ischemia; and superaventicular tachyarrhytmia.
A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
brevets